CAPECITABINE Side Effects

7018225-8 | Neutropenia, Sepsis
on Sep 21, 2010 Female patient from JAPAN , weighting 90.39 lb, was diagnosed with gastric cancer and was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenia, sepsis (What is sepsis?). Capecitabine dosage: Reported As: Xeloda 300, Note: 2 Weeks Administration Followed By 1 Week Rest.. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), ERBITUX (View Erbitux Review and Erbitux Label ).

7018154-X | Diabetic Ketoacidosis, Neutropenic Sepsis
Patient was taking Capecitabine (View Usage). Patient had the following side effects: diabetic ketoacidosis, neutropenic sepsis on Sep 20, 2010 from UNITED KINGDOM Additional patient health information: Female patient , 73 years of age, weighting 110.2 lb, was diagnosed with rectal cancer and. Capecitabine dosage: . During the same period patient was treated with BECLOMETHASONE DIPROPIONATE (View Beclomethasone Dipropionate Review and Beclomethasone Dipropionate Label ).

7018121-6 | Abasia, Abdominal Pain, Blood Pressure Increased, Diarrhoea, Erythema, Feeling Abnormal, Fluid Retention, Loss Of Consciousness, Oropharyngeal Blistering
Adverse event was reported on Sep 20, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: Route: By Mouth) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED STATES , weighting 134.9 lb, After Capecitabine was administered, patient had the following side effects: abasia, abdominal pain (What is abdominal pain?), blood pressure increased, diarrhoea, erythema, feeling abnormal, fluid retention, loss of consciousness, oropharyngeal blistering. During the same period patient was treated with OXALIPLATIN (Form: Infusion) (View Oxaliplatin Review and Oxaliplatin Label ).

7014687-0 | Colon Cancer Metastatic, Device Related Sepsis, Fanconi Syndrome, Haemoglobin Decreased, Hypokalaemia, Ileus Paralytic, Malignant Neoplasm Progression, Metabolic Acidosis, Nephropathy Toxic
on Sep 20, 2010 Female patient from ISRAEL , 63 years of age, was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: colon cancer metastatic, device related sepsis, fanconi syndrome, haemoglobin decreased, hypokalaemia, ileus paralytic, malignant neoplasm progression, metabolic acidosis, nephropathy toxic. Capecitabine dosage: On Days 1 To 14 Every 3 Weeks. During the same period patient was treated with NEUPOGEN (View Neupogen Review and Neupogen Label ), CETUXIMAB (Loading Dose) (View Cetuximab Review and Cetuximab Label ), OXALIPLATIN (Day 1, Every 2 Weeks) (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.


7014629-8 | Blood Creatinine Increased, Dehydration, Diarrhoea, Ileus Paralytic, Neutrophil Count Decreased, Pneumonia, White Blood Cell Count Decreased
on Sep 17, 2010 Male patient from JAPAN , weighting 142.2 lb, was diagnosed with colon cancer metastatic and was treated with Capecitabine (View Usage). Patient had the following side effects: blood creatinine increased, dehydration, diarrhoea, ileus paralytic, neutrophil count decreased, pneumonia (What is pneumonia?), white blood cell count decreased. Capecitabine dosage: . During the same period patient was treated with ELPLAT (View Elplat Review and Elplat Label ). Patient was hospitalized.

7014606-7 | Femur Fracture
Patient was taking Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: femur fracture on Sep 16, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 149.5 lb, . Capecitabine dosage: 800 Mg/m2, Bid. During the same period patient was treated with LAPATINIB (750 Mg, Qd) (View Lapatinib Review and Lapatinib Label ). Patient was hospitalized and became disabled.

7012637-4 | Cystitis, Proctitis
Adverse event was reported on Sep 15, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: Dose Prior To Event: 29 Mar 2010, Dose At Last Admin: 2x1500 Mg, Paused From 30/03/10 To 5/04/10) was diagnosed with rectal cancer and. Location: GERMANY , weighting 220.5 lb, Patient experienced the following unwanted or unexpected effects: cystitis, proctitis. During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized and became disabled.

7009854-6 | Anal Abscess, Diarrhoea, Pyrexia
on Sep 14, 2010 Female patient from NETHERLANDS , weighting 163.6 lb, was diagnosed with gastric cancer and was treated with Capecitabine (View Usage). Patient had the following side effects: anal abscess, diarrhoea, pyrexia. Capecitabine dosage: Dose, Route, Frequency Captured As Per Protocol. During the same period patient was treated with EPIRUBICIN (Route, Dose, Frequency Captured As Per Protocol) (View Epirubicin Review and Epirubicin Label ), CISPLATIN (Route, Dose, Frequency Captured As Per Protocol) (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

7009788-7 | Guillain-barre Syndrome, Hyponatraemia, Peripheral Motor Neuropathy, Peripheral Sensory Neuropathy, Respiratory Distress
on Sep 13, 2010 Male patient from FRANCE , 45 years of age, weighting 180.1 lb, was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: guillain-barre syndrome (What is guillain-barre syndrome?), hyponatraemia, peripheral motor neuropathy, peripheral sensory neuropathy, respiratory distress. Capecitabine dosage: Form: Pills. During the same period patient was treated with OXALIPLATIN (Route: Subcutaneous) (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

7007803-8 | Ileus, Intestinal Dilatation, Intestinal Obstruction
Patient was taking Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: ileus, intestinal dilatation, intestinal obstruction on Sep 13, 2010 from GERMANY Additional patient health information: Female patient , weighting 125.7 lb, was diagnosed with rectal cancer, unevaluable event, nausea (What is nausea?), hypertension and. Capecitabine dosage: Frequency:day 1 And 15 Of 3 Week Cycle. Actual Dose Given:1500mg. Last Dose Prior To Sae: 6 Aug 2010. During the same period patient was treated with OXALIPLATIN (Frequency: Day 1 Of 3 Weeks Cycle. Actual Dose Received:211mg. Last Dose Prior To Sae: 26 Jul 2010) (View Oxaliplatin Review and Oxaliplatin Label ), PANTOPRAZOLE SODIUM (Schedule Reported As 20g- 0 -20g) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), VERGENTAN (Schedule Reported As 2x1) (View Vergentan Review and Vergentan Label ), DEXA (View Dexa Review and Dexa Label ), MCP (Dose Reported As 3x5 Mg) (View Mcp Review and Mcp Label ), ENALAPRIL MALEATE (Once A Day) (View Enalapril Maleate Review and Enalapril Maleate Label ), METOPROLOL (View Metoprolol Review and Metoprolol Label ). Patient was hospitalized.

7005489-X | Abdominal Distension, Amnesia, Diarrhoea, Fatigue
Adverse event was reported on Sep 10, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: ) . Location: UNITED STATES , weighting 119.9 lb, Patient had the following side effects: abdominal distension, amnesia, diarrhoea, fatigue. During the same period patient was treated with COUMADIN (View Coumadin Review and Coumadin Label ). Patient was hospitalized.

7005436-0 | Myocardial Infarction
on Sep 13, 2010 Male patient from UNITED KINGDOM , 74 years of age, weighting 235.9 lb, was diagnosed with colon cancer and was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: myocardial infarction. Capecitabine dosage: . During the same period patient was treated with ASPIRIN (View Aspirin Review and Aspirin Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), FERROUS SULFATE TAB (Active Constituent Reported As: Iron) (View Ferrous Sulfate Tab Review and Ferrous Sulfate Tab Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), ZOPICLONE (View Zopiclone Review and Zopiclone Label ).

7005401-3 | Pelvic Fracture, Wrist Fracture
on Sep 09, 2010 Female patient from GERMANY , 80 years of age, weighting 103.6 lb, was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: pelvic fracture, wrist fracture. Capecitabine dosage: . Patient was hospitalized.

7001521-8 | Cerebral Infarction, Jaundice Cholestatic
Patient was taking Capecitabine (View Usage). Patient had the following side effects: cerebral infarction, jaundice cholestatic on Sep 08, 2010 from JAPAN Additional patient health information: Male patient , weighting 116.8 lb, was diagnosed with gastrooesophageal cancer and. Capecitabine dosage: 2 Weeks Administration Followed By 1 Week Rest.. During the same period patient was treated with CISPLATIN (Route: Intravenous (not Otherwise Specified). Dosage Is Uncertain.) (View Cisplatin Review and Cisplatin Label ), ERBITUX (Route: Intravenous (not Otherwise Specified). Dosage Is Uncertain.) (View Erbitux Review and Erbitux Label ), TEPRENONE (From: Peroral Agent) (View Teprenone Review and Teprenone Label ), OXYCODONE HCL (Form: Peroral Agent) (View Oxycodone Hcl Review and Oxycodone Hcl Label ), PROCHLORPERAZINE (Form: Peroral Agent) (View Prochlorperazine Review and Prochlorperazine Label ), FERROUS SULFATE (Form: Peroral Agent) (View Ferrous Sulfate Review and Ferrous Sulfate Label ), LANSOPRAZOLE (Route: Intravenous (not Otherwise Specified)) (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized.

7001502-4 | Aphasia, Asthenia, Convulsion, Neutropenia, Pyrexia
Adverse event was reported on Sep 13, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: In Divided Doses, From Day 1-14 Every 3 Weeks, Strength 500 Mg Or 150 Mg Tablet As Per Protocol) was diagnosed with gastric cancer and. Location: NETHERLANDS , weighting 167.6 lb, After Capecitabine was administered, patient had the following side effects: aphasia (What is aphasia?), asthenia, convulsion, neutropenia, pyrexia. During the same period patient was treated with EPIRUBICIN (Day 1, Dosage As Per Protocol) (View Epirubicin Review and Epirubicin Label ), CISPLATIN (Day 1, Dosage As Per Protocol) (View Cisplatin Review and Cisplatin Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), COAPROVEL (View Coaprovel Review and Coaprovel Label ), PRIMPERAN TAB (View Primperan Tab Review and Primperan Tab Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

7001079-3 | Renal Infarct
on Sep 09, 2010 Female patient from UNITED STATES , weighting 110.2 lb, was diagnosed with breast cancer (What is breast cancer?), ovarian failure and was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: renal infarct. Capecitabine dosage: Given On Day 1 To Day 14 Per Three Weeks. During the same period patient was treated with SUNITINIB MALATE (View Sunitinib Malate Review and Sunitinib Malate Label ), ZOLADEX (View Zoladex Review and Zoladex Label ).

6994452-0 |
on Sep 10, 2010 Female patient from GERMANY , weighting 127.9 lb, was diagnosed with breast cancer metastatic, abdominal pain (What is abdominal pain?), rib fracture, thyroid disorder, nausea (What is nausea?), oedema and was treated with Capecitabine (View Usage). . Capecitabine dosage: . During the same period patient was treated with TRAMADOL HYDROCHLORIDE (View Tramadol Hydrochloride Review and Tramadol Hydrochloride Label ), EUTHYROX (View Euthyrox Review and Euthyrox Label ), VOMEX (View Vomex Review and Vomex Label ), PASPERTIN (20-25 Drops) (View Paspertin Review and Paspertin Label ), LASIX (View Lasix Review and Lasix Label ).

6992600-X | Abdominal Pain Lower, Hyperlipasaemia
Patient was taking Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: abdominal pain lower, hyperlipasaemia on Sep 07, 2010 from GERMANY Additional patient health information: Female patient , weighting 121.3 lb, . Capecitabine dosage: The 3rd Cycle Was Started On 23-aug-2010. During the same period patient was treated with OXALIPLATIN (The 3rd Cycle, Administration On Day 1 Was Started On 23-aug-2010) (View Oxaliplatin Review and Oxaliplatin Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), SELEN (View Selen Review and Selen Label ).

6992538-8 | Malignant Neoplasm Progression
Adverse event was reported on Sep 09, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: Cycle 1 And 2) . Location: GERMANY , 61 years of age, weighting 132.3 lb, Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression. During the same period patient was treated with VINORELBIN (View Vinorelbin Review and Vinorelbin Label ).

6988179-9 | Malignant Neoplasm Progression
on Sep 09, 2010 Female patient from FRANCE , 65 years of age, weighting 147.7 lb, was treated with Capecitabine (View Usage). Patient had the following side effects: malignant neoplasm progression. Capecitabine dosage: Dose Cyclic.

6988155-6 | Neutropenia, Pancreatitis Acute
on Sep 06, 2010 Male patient from GERMANY , weighting 188.5 lb, was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: neutropenia, pancreatitis acute. Capecitabine dosage: Frequency Reported: Split In 2 Daily Dosages. Last Dose Prior To Sae: 15 January 2010. During the same period patient was treated with DOCETAXEL (Frequency Reported: 1x) (View Docetaxel Review and Docetaxel Label ), CISPLATIN (Frequency Reported: 1x. Last Dose Prior To Sae: 6 January 2010.) (View Cisplatin Review and Cisplatin Label ), TEPILTA (2 (bre) Sachet.) (View Tepilta Review and Tepilta Label ). Patient was hospitalized.

6985136-3 | Neutropenia, Pancreatitis Acute
Patient was taking Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenia, pancreatitis acute on Sep 06, 2010 from GERMANY Additional patient health information: Male patient , weighting 188.5 lb, . Capecitabine dosage: Frequency Reported: Split In 2 Daily Dosages. Last Dose Prior To Sae: 15 January 2010. During the same period patient was treated with DOCETAXEL (Frequency Reported: 1x) (View Docetaxel Review and Docetaxel Label ), CISPLATIN (Frequency Reported: 1x. Last Dose Prior To Sae: 6 January 2010.) (View Cisplatin Review and Cisplatin Label ), TEPILTA (2 (bre) Sachet.) (View Tepilta Review and Tepilta Label ). Patient was hospitalized.

6980222-6 | Malignant Neoplasm Progression
Adverse event was reported on Sep 02, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: ) . Location: GERMANY , 47 years of age, weighting 152.1 lb, Patient had the following side effects: malignant neoplasm progression. During the same period patient was treated with AVASTIN (View Avastin Review and Avastin Label ), BONDRONAT (View Bondronat Review and Bondronat Label ), TAXOL (View Taxol Review and Taxol Label ).

6979933-8 | Ischaemic Stroke
on Sep 06, 2010 Female patient from HUNGARY , weighting 167.6 lb, was diagnosed with breast cancer metastatic, rash maculo-papular, acne (What is acne?) and was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: ischaemic stroke. Capecitabine dosage: . During the same period patient was treated with LORATADINE (Not Provided) (View Loratadine Review and Loratadine Label ), CLINDAMYCIN HYDROCHLORIDE (Not Provided) (View Clindamycin Hydrochloride Review and Clindamycin Hydrochloride Label ), LAPATINIB (View Lapatinib Review and Lapatinib Label ). Patient was hospitalized.

6978612-0 | Cerebral Infarction, Jaundice Cholestatic
on Sep 02, 2010 Male patient from JAPAN , weighting 116.8 lb, was diagnosed with gastrooesophageal cancer and was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral infarction, jaundice cholestatic. Capecitabine dosage: 2 Weeks Administration Followed By 1 Week Rest.. During the same period patient was treated with CISPLATIN (Route: Intravenous (not Otherwise Specified). Dosage Is Uncertain.) (View Cisplatin Review and Cisplatin Label ), ERBITUX (Route: Intravenous (not Otherwise Specified). Dosage Is Uncertain.) (View Erbitux Review and Erbitux Label ), TEPRENONE (From: Peroral Agent) (View Teprenone Review and Teprenone Label ), OXYCODONE HCL (Form: Peroral Agent) (View Oxycodone Hcl Review and Oxycodone Hcl Label ), PROCHLORPERAZINE (Form: Peroral Agent) (View Prochlorperazine Review and Prochlorperazine Label ), FERROUS SULFATE (Form: Peroral Agent) (View Ferrous Sulfate Review and Ferrous Sulfate Label ), LANSOPRAZOLE (Route: Intravenous (not Otherwise Specified)) (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized.

6978606-5 | Diarrhoea, Nausea, Pyrexia
Patient was taking Capecitabine (View Usage). Patient had the following side effects: diarrhoea, nausea (What is nausea?), pyrexia on Sep 03, 2010 from BELGIUM Additional patient health information: Female patient , weighting 216.1 lb, was diagnosed with rectal cancer and. Capecitabine dosage: Bid D1-33. Date Of Last Dose Prior To Sae: 18 July 2010. During the same period patient was treated with OXALIPLATIN (Date Of Last Dose Prior To Sae: 12 July 2010) (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

6978589-8 | Failure To Anastomose, Pelvic Abscess, Pleural Effusion, Renal Failure Acute
Adverse event was reported on Sep 02, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: D1-33 W/o Weekends, Actual Dose Given (as Last Administration): 1500 Mg. Dose Prior Sae:15 Feb 2010) was diagnosed with rectal cancer, nausea (What is nausea?), hypertension and. Location: GERMANY , weighting 108.0 lb, After Capecitabine was administered, patient had the following side effects: failure to anastomose, pelvic abscess, pleural effusion, renal failure acute. During the same period patient was treated with IMODIUM (View Imodium Review and Imodium Label ), PASPERTIN (View Paspertin Review and Paspertin Label ), PANTOPRAZOLE SODIUM (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), REMERGIL (View Remergil Review and Remergil Label ), METOPROLOL SUCCINATE (View Metoprolol Succinate Review and Metoprolol Succinate Label ), TOREM (View Torem Review and Torem Label ). Patient was hospitalized.

6977049-8 | Malignant Neoplasm Progression
on Sep 03, 2010 Female patient from GERMANY , 66 years of age, was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: malignant neoplasm progression. Capecitabine dosage: .

6977039-5 | Colitis, Embolic Stroke, Enteritis, Leukopenia, Neutropenia
on Aug 30, 2010 Male patient from GERMANY , weighting 127.9 lb, was diagnosed with metastatic gastric cancer, herpes simplex (What is herpes simplex?) and was treated with Capecitabine (View Usage). Patient had the following side effects: colitis, embolic stroke, enteritis, leukopenia, neutropenia. Capecitabine dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), EPIRUBICIN (View Epirubicin Review and Epirubicin Label ), ACYCLOVIR SODIUM (View Acyclovir Sodium Review and Acyclovir Sodium Label ), ASPIRIN (View Aspirin Review and Aspirin Label ). Patient was hospitalized.

6977007-3 | Pancreatitis
Patient was taking Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: pancreatitis on Sep 02, 2010 from GERMANY Additional patient health information: Male patient , weighting 218.5 lb, was diagnosed with colorectal cancer stage iv and. Capecitabine dosage: Dose: 2000 Mg Twice Daily From Day1- Day 14.. During the same period patient was treated with BEVACIZUMAB (View Bevacizumab Review and Bevacizumab Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), IMATINIB (Dose: 300 Mg Daily From Day-1 To Day 21.) (View Imatinib Review and Imatinib Label ). Patient was hospitalized.

6970452-1 | Duodenal Ulcer Perforation, Respiratory Failure
Adverse event was reported on Sep 03, 2010 by a Male patient taking Capecitabine (View Usage) (Dosage: Frequency: Bid D1-33 W/o Weekend + Optional, Actual Dose Given Prior To Sae Was 1500 Mg.) was diagnosed with rectal cancer and. Location: GERMANY , weighting 125.7 lb, Patient experienced the following unwanted or unexpected effects: duodenal ulcer perforation, respiratory failure. Patient was hospitalized.

6968362-9 | Pulmonary Embolism
on Aug 31, 2010 Male patient from UNITED KINGDOM , weighting 165.3 lb, was treated with Capecitabine (View Usage). Patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Capecitabine dosage: Last Dose Prior To Sae: 09 June 2010.. During the same period patient was treated with CISPLATIN (Last Dose Prior To Sae: 19 May 2010.) (View Cisplatin Review and Cisplatin Label ), EPIRUBICIN (Last Dose Prior To Sae: 19 May 2010.) (View Epirubicin Review and Epirubicin Label ).

6968293-4 | Dehydration, Vertigo
on Aug 24, 2010 Female patient from GERMANY , weighting 138.9 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: dehydration, vertigo. Capecitabine dosage: Dose Route Taken From Protocol.temporarily Interrupted.. During the same period patient was treated with BEVACIZUMAB (Dose And Route Taken From Protocol.last Dose Prior To Sae 22 July 2010.temporarily Interrupted) (View Bevacizumab Review and Bevacizumab Label ), MCP (Frequency:as Required) (View Mcp Review and Mcp Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), LOPERAMIDE (As Required) (View Loperamide Review and Loperamide Label ), VOMEX A (View Vomex A Review and Vomex A Label ). Patient was hospitalized.

6968291-0 | Intestinal Dilatation, Intestinal Obstruction
Patient was taking Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: intestinal dilatation, intestinal obstruction on Aug 30, 2010 from GERMANY Additional patient health information: Female patient , weighting 125.7 lb, was diagnosed with rectal cancer, unevaluable event, nausea (What is nausea?), hypertension and. Capecitabine dosage: Frequency:day 1 And 15 Of 3 Week Cycle. Actual Dose Given:1500mg. Last Dose Prior To Sae: 6 Aug 2010. During the same period patient was treated with OXALIPLATIN (Frequency: Day 1 Of 3 Weeks Cycle. Actual Dose Received:211mg. Last Dose Prior To Sae: 26 Jul 2010) (View Oxaliplatin Review and Oxaliplatin Label ), PANTOPRAZOLE SODIUM (Schedule Reported As 20g- 0 -20g) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), VERGENTAN (Schedule Reported As 2x1) (View Vergentan Review and Vergentan Label ), DEXA (View Dexa Review and Dexa Label ), MCP (Dose Reported As 3x5 Mg) (View Mcp Review and Mcp Label ), ENALAPRIL (Once A Day) (View Enalapril Review and Enalapril Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ). Patient was hospitalized.

6966345-6 |
Adverse event was reported on Sep 01, 2010 by a Male patient taking Capecitabine (View Usage) (Dosage: ) . Location: UNITED STATES , 73 years of age, weighting 270.1 lb, . During the same period patient was treated with SUNITINIB MALATE (Form: Capsule Hard.) (View Sunitinib Malate Review and Sunitinib Malate Label ), AVODART (View Avodart Review and Avodart Label ), FLOMAX (View Flomax Review and Flomax Label ), IMODIUM (View Imodium Review and Imodium Label ).

6965678-7 | Anastomotic Leak
on Aug 27, 2010 Male patient from GERMANY , weighting 183.0 lb, was diagnosed with colorectal cancer (What is colorectal cancer?), nausea (What is nausea?) and was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: anastomotic leak. Capecitabine dosage: 825 Mg/m2 Per Oral Bid (twice A Day), Day 1 To Day 33 Without Weekends+optional Boost.. During the same period patient was treated with ONDANSETRON (View Ondansetron Review and Ondansetron Label ), MCP (Dose 30 Per Day, Unit Was Not Provided.) (View Mcp Review and Mcp Label ), CIPRO (View Cipro Review and Cipro Label ). Patient was hospitalized.

6965645-3 | Pelvic Fracture, Wrist Fracture
on Sep 01, 2010 Female patient from GERMANY , 80 years of age, weighting 103.6 lb, was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: pelvic fracture, wrist fracture. Capecitabine dosage: . Patient was hospitalized.

6965594-0 | Malignant Neoplasm Progression
Patient was taking Capecitabine (View Usage). Patient had the following side effects: malignant neoplasm progression on Aug 26, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 101.0 lb, was diagnosed with breast cancer (What is breast cancer?) and. Capecitabine dosage: 7 Days On 7 Days Off.

6965574-5 | Peritonitis, Tumour Perforation
Adverse event was reported on Aug 26, 2010 by a Male patient taking Capecitabine (View Usage) (Dosage: From Day 1 To Day 14 Of Cycle) was diagnosed with metastatic gastric cancer, gastroduodenal ulcer, antiemetic supportive care and. Location: UNITED STATES , 50 years of age, weighting 155.6 lb, After Capecitabine was administered, patient had the following side effects: peritonitis, tumour perforation. During the same period patient was treated with SUTENT (2 Weeks On And 1 Week Off) (View Sutent Review and Sutent Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), FAMOTIDINE (View Famotidine Review and Famotidine Label ), GRANISETRON HCL (View Granisetron Hcl Review and Granisetron Hcl Label ), LANSOPRAZOLE (View Lansoprazole Review and Lansoprazole Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), CHLORPHENIRAMINE MALEATE (View Chlorpheniramine Maleate Review and Chlorpheniramine Maleate Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ). Patient was hospitalized.

6965570-8 | Dehydration, Vertigo
on Aug 23, 2010 Female patient from GERMANY , weighting 138.9 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: dehydration, vertigo. Capecitabine dosage: Dose Route Taken From Protocol.temporarily Interrupted.. During the same period patient was treated with BEVACIZUMAB (Dose And Route Taken From Protocol.last Dose Prior To Sae 22 July 2010.temporarily Interrupted) (View Bevacizumab Review and Bevacizumab Label ), MCP (Frequency:as Required) (View Mcp Review and Mcp Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ), LOPERAMIDE (As Required) (View Loperamide Review and Loperamide Label ), VOMEX A (View Vomex A Review and Vomex A Label ). Patient was hospitalized.

6965139-5 | Renal Infarct
on Aug 24, 2010 Female patient from FRANCE , 41 years of age, weighting 114.6 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Capecitabine (View Usage). Patient had the following side effects: renal infarct. Capecitabine dosage: 1500 Mg, 2x/day, Day 1-14, Every 3 Wks. During the same period patient was treated with SUNITINIB MALATE (37.5 Mg, 1x/day) (View Sunitinib Malate Review and Sunitinib Malate Label ), ZOLADEX (Unk) (View Zoladex Review and Zoladex Label ).

6962956-2 | Abdominal Pain, Decreased Appetite, Diarrhoea, Gastrointestinal Motility Disorder, Lymphorrhoea, Nausea, Pneumonitis
Patient was taking Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), decreased appetite, diarrhoea, gastrointestinal motility disorder, lymphorrhoea, nausea (What is nausea?), pneumonitis on Aug 26, 2010 from NETHERLANDS Additional patient health information: Male patient , weighting 125.2 lb, was diagnosed with gastric cancer and. Capecitabine dosage: Last Dose Prior To Sae: 20 April 2008, D1-14 Every 3 Weeks.route,form,dosage Per Protocol. During the same period patient was treated with EPIRUBICIN (On Day 1; Last Dose Prior To Sae:20 Apr 2008, Route,form,dosage Per Protocol) (View Epirubicin Review and Epirubicin Label ), CISPLATIN (On Day 1; Last Dose Prior To Sae:20 Apr 2008, Route,form,dosage Per Protocol) (View Cisplatin Review and Cisplatin Label ), OMEPRAZOLE (Dose: 2 X 40 Mg) (View Omeprazole Review and Omeprazole Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), MOVICOLON (Dose Reported As : 1 Sachet /day) (View Movicolon Review and Movicolon Label ), NEXIUM (View Nexium Review and Nexium Label ), LOPERAMIDE (View Loperamide Review and Loperamide Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ). Patient was hospitalized.

6962947-1 | Cerebral Infarction
Adverse event was reported on Aug 25, 2010 by a Male patient taking Capecitabine (View Usage) (Dosage: 2 Weeks Administration Followed By 1 Week Rest.) was diagnosed with gastrooesophageal cancer and. Location: JAPAN , weighting 116.8 lb, Patient experienced the following unwanted or unexpected effects: cerebral infarction. During the same period patient was treated with CISPLATIN (Route: Intravenous (not Otherwise Specified). Dosage Is Uncertain. Last Dose Prior To Sae: 27 Jul10) (View Cisplatin Review and Cisplatin Label ), ERBITUX (Route: Intravenous (not Otherwise Specified). Dosage Is Uncertain. Last Dose Prior To Sae: 27 Jul 10) (View Erbitux Review and Erbitux Label ), TEPRENONE (From: Peroral Agent) (View Teprenone Review and Teprenone Label ), OXYCODONE HCL (Form: Peroral Agent) (View Oxycodone Hcl Review and Oxycodone Hcl Label ), PROCHLORPERAZINE (Form: Peroral Agent) (View Prochlorperazine Review and Prochlorperazine Label ), FERROUS SULFATE (Form: Peroral Agent) (View Ferrous Sulfate Review and Ferrous Sulfate Label ), LANSOPRAZOLE (Route: Intravenous (not Otherwise Specified)) (View Lansoprazole Review and Lansoprazole Label ). Patient was hospitalized.

6962636-3 | Renal Infarct
on Aug 24, 2010 Female patient from FRANCE , 41 years of age, weighting 114.6 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Capecitabine (View Usage). Patient had the following side effects: renal infarct. Capecitabine dosage: 1500 Mg, 2x/day, Day 1-14, Every 3 Wks. During the same period patient was treated with SUNITINIB MALATE (37.5 Mg, 1x/day) (View Sunitinib Malate Review and Sunitinib Malate Label ), ZOLADEX (Unk) (View Zoladex Review and Zoladex Label ).

6961769-5 | Neutropenic Sepsis
on Aug 18, 2010 Female patient from ITALY , 82 years of age, was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: neutropenic sepsis. Capecitabine dosage: Taken For 14 Consecutive Days With Cycles Repeated Every 3 Weeks. During the same period patient was treated with IRINOTECAN HCL (Form: Infusion, 80 Mg/m2/day Taken On Days 1 And 8 As A 3-h Iv Infusion) (View Irinotecan Hcl Review and Irinotecan Hcl Label ).

6960854-1 | Myocardial Infarction
Patient was taking Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: myocardial infarction on Aug 18, 2010 from ITALY Additional patient health information: Female patient , 72 years of age, . Capecitabine dosage: Taken For 14 Consecutive Days With Cycles Repeated Every 3 Weeks. During the same period patient was treated with OXALIPLATIN (Form: Infusion, 65 Mg/m2/day Taken On Days 1 And 8 As A 3-h Iv Infusion) (View Oxaliplatin Review and Oxaliplatin Label ).

6960833-4 | Diarrhoea, Dysphagia
Adverse event was reported on Aug 18, 2010 by a Female patient taking Capecitabine (View Usage) (Dosage: Unk Mg/m2, Qd) . Location: UNITED STATES , weighting 112.4 lb, Patient had the following side effects: diarrhoea, dysphagia. During the same period patient was treated with LAPATINIB (Unk Mg, Unk) (View Lapatinib Review and Lapatinib Label ). Patient was hospitalized.

6960808-5 | Anastomotic Leak
on Aug 27, 2010 Male patient from GERMANY , weighting 1830 lb, was diagnosed with colorectal cancer (What is colorectal cancer?), nausea (What is nausea?) and was treated with Capecitabine (View Usage). After Capecitabine was administered, patient had the following side effects: anastomotic leak. Capecitabine dosage: 825 Mg/m2 Per Oral Bid (twice A Day), Day 1 To Day 33 Without Weekends+optional Boost.. During the same period patient was treated with ONDANSETRON (View Ondansetron Review and Ondansetron Label ), MCP (Dose 30 Per Day, Unit Was Not Provided.) (View Mcp Review and Mcp Label ), CIPRO (View Cipro Review and Cipro Label ). Patient was hospitalized.

6960676-1 | Malaise, Pyrexia, Radiation Oesophagitis
on Aug 26, 2010 Female patient from NETHERLANDS , weighting 174.2 lb, was diagnosed with gastric cancer and was treated with Capecitabine (View Usage). Patient experienced the following unwanted or unexpected effects: malaise, pyrexia, radiation oesophagitis. Capecitabine dosage: Dose Per Protocol. Orally In 2 Equally Divided Doses, 1000 Mg/m2 Bid, Day 1-14 Every 3 Weeks.. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), EPIRUBICIN (View Epirubicin Review and Epirubicin Label ). Patient was hospitalized.

6958850-3 | Diarrhoea, Fatigue, Hypokalaemia
Patient was taking Capecitabine (View Usage). Patient had the following side effects: diarrhoea, fatigue, hypokalaemia on Aug 20, 2010 from SPAIN Additional patient health information: Female patient , weighting 127.9 lb, was diagnosed with breast cancer metastatic, hypertension, gastritis prophylaxis, anxiety (What is anxiety?), depression (What is depression?), venous insufficiency and. Capecitabine dosage: 3200 Mg 2 Weeks Every 3. During the same period patient was treated with ENALAPRIL MALEATE (Not Provided) (View Enalapril Maleate Review and Enalapril Maleate Label ), OMEPRAZOLE (Not Provided) (View Omeprazole Review and Omeprazole Label ), BROMAZEPAM (Not Provided) (View Bromazepam Review and Bromazepam Label ), PAROXETINE HCL (Not Provided) (View Paroxetine Hcl Review and Paroxetine Hcl Label ), DIOSMIN (Not Provided) (View Diosmin Review and Diosmin Label ), LAPATINIB (1500 Mg) (View Lapatinib Review and Lapatinib Label ). Patient was hospitalized.